About 80% of medical cannabis users with chronic pain reported substituting it for traditional pain medications

80% of 1,321 medical cannabis users with chronic pain reported substituting cannabis for traditional pain medications: 53% for opioids, 22% for benzodiazepines. Reasons cited were fewer side effects and better symptom management. Experienced users (1+ years) were more likely to take no concomitant pain medications (43% vs 30%) and report improved health (74% vs 67%).

Ongoing nationwide online survey of medical cannabis users with chronic pain. 1,321 participants (59% female, 54% aged 50+). Examined effects of cannabis on pain management, health, and medication use, stratified by recreational co-use and duration of cannabis experience.

Chronic pain is the most common reason for medical cannabis licenses. If cannabis consistently enables patients to reduce opioid and benzodiazepine use, it has direct implications for the opioid crisis and benzodiazepine dependency epidemic.

The high substitution rate and the finding that experienced users are more likely to eliminate other medications suggest cannabis may function as a practical opioid exit ramp for chronic pain patients. The public health implications are significant.

Self-reported data from medical cannabis users, biased toward those who found cannabis helpful. No clinical verification of medication changes. Cross-sectional design. No pain severity or functional outcome measures. Cannot determine whether substitution is medically appropriate.